A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD)

Registry ID

SHP677-304

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BAXALTA INNOVATIONS GMBH

Last update

2019-07-17

Conditions

• VON WILLEBRAND DISEASE

Related clinical trials

• A PHASE III, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH TYPE 3 VON WILLEBRAND DISEASE
• A SAFETY, TOLERABILITY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF VGA039 FOLLOWING INTRAVENOUS OR SUBCUTANEOUS ADMINISTRATION OF SINGLE ASCENDING DOSES IN HEALTHY ADULTS AND ADULT PATIENTS WITH VON WILLEBRAND DISEASE

View on source registry